“…This therapy is used in palliative care as a strategy to provide relief from refractory symptoms, such as delirium, dyspnoea, psychological suffering and pain, among others (Altisent et al., ; De Graeff & Dean, ; Maltoni, Scarpi, & Nanni, ; Schildmann & Schildmann, ). Although its administration is more common every day and there are several guidelines available, it is still a subject of much clinical, legal and ethical debate in different contexts (Abarshi et al., ; Leboul et al., ; Melia, ; Raus et al., ; Verkerk, van Wijlick, Legemaate, & de Graeff, ). Most guidelines on PS and studies regarding its use derive from developed countries (Abarshi et al., ; Schildmann & Schildmann, ) and data regarding guidelines, practices and perceptions of healthcare providers in developing regions (e.g., Latin America) are very scarce (Moyano, Zambrano, Ceballos, Santacruz, & Guerrero, ; Pelluchon, ; Soriano, Lima, Batista, Febles, & Morales, ; Spineli, Kurashima, & De Gutiérrez, ).…”